[{"address1": "490 Arsenal Way", "address2": "Suite120", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 231 0700", "website": "https://www.c4therapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 110, "companyOfficers": [{"maxAge": 1, "name": "Mr. Andrew J. Hirsch M.B.A.", "age": 54, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1081125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kenneth C. Anderson M.D., Ph.D.", "age": 74, "title": "Co-Founder, Independent Director & Member of Scientific Advisory Board", "yearBorn": 1951, "fiscalYear": 2024, "totalPay": 45000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kendra  Adams", "title": "Chief Financial Officer and Head of Corporate Affairs & Treasurer", "fiscalYear": 2024, "totalPay": 711215, "exercisedValue": 0, "unexercisedValue": 50296}, {"maxAge": 1, "name": "Dr. Leonard M. J. Reyno M.D.", "age": 63, "title": "Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 837480, "exercisedValue": 0, "unexercisedValue": 8625}, {"maxAge": 1, "name": "Dr. Nathanael S. Gray Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Mossler", "age": 51, "title": "Chief Accounting Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paige  Mahaney Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney  Solberg", "title": "Senior Manager of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly A. Schick", "age": 45, "title": "Chief People Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Isabel  Chiu Ph.D.", "title": "Senior Vice President of Strategic Alliances & Business Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.96, "open": 1.95, "dayLow": 1.83, "dayHigh": 1.96, "regularMarketPreviousClose": 1.96, "regularMarketOpen": 1.95, "regularMarketDayLow": 1.83, "regularMarketDayHigh": 1.96, "payoutRatio": 0.0, "beta": 2.941, "forwardPE": -1.4766802, "volume": 1666266, "regularMarketVolume": 1666266, "averageVolume": 1640470, "averageVolume10days": 1795670, "averageDailyVolume10Day": 1795670, "bid": 1.87, "ask": 1.92, "bidSize": 3, "askSize": 5, "marketCap": 184137392, "fiftyTwoWeekLow": 1.085, "fiftyTwoWeekHigh": 3.72, "allTimeHigh": 51.21, "allTimeLow": 1.06, "priceToSalesTrailing12Months": 6.1158957, "fiftyDayAverage": 2.2794, "twoHundredDayAverage": 2.12035, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 53716396, "profitMargins": 0.0, "floatShares": 61737392, "sharesOutstanding": 96914418, "sharesShort": 7379826, "sharesShortPriorMonth": 7172653, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0761, "heldPercentInsiders": 0.07196, "heldPercentInstitutions": 0.7377, "shortRatio": 4.4, "shortPercentOfFloat": 0.0805, "impliedSharesOutstanding": 96914418, "bookValue": 2.082, "priceToBook": 0.912584, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -119081000, "trailingEps": -1.61, "forwardEps": -1.28667, "enterpriseToRevenue": 1.784, "enterpriseToEbitda": -0.459, "52WeekChange": -0.4166667, "SandP52WeekChange": 0.16255379, "quoteType": "EQUITY", "currentPrice": 1.9, "targetHighPrice": 20.0, "targetLowPrice": 5.0, "targetMeanPrice": 9.85714, "targetMedianPrice": 7.0, "recommendationMean": 1.125, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 191884000, "totalCashPerShare": 1.98, "ebitda": -117042000, "totalDebt": 61463000, "quickRatio": 5.52, "currentRatio": 5.755, "totalRevenue": 30108000, "debtToEquity": 39.806, "revenuePerShare": 0.423, "returnOnAssets": -0.23196, "returnOnEquity": -0.59981, "grossProfits": -81663000, "freeCashflow": -54987124, "operatingCashflow": -94481000, "revenueGrowth": -0.269, "grossMargins": -2.71234, "ebitdaMargins": 0.0, "operatingMargins": -2.10855, "financialCurrency": "USD", "symbol": "CCCC", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "priceEpsCurrentYear": -1.25, "fiftyDayAverageChange": -0.37940013, "fiftyDayAverageChangePercent": -0.16644736, "twoHundredDayAverageChange": -0.22034991, "twoHundredDayAverageChangePercent": -0.10392149, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-02", "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1769818885, "regularMarketTime": 1769806802, "exchange": "NMS", "messageBoardId": "finmb_321572356", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "C4 Therapeutics, Inc.", "longName": "C4 Therapeutics, Inc.", "fiftyTwoWeekLowChange": 0.81499994, "fiftyTwoWeekLowChangePercent": 0.751152, "fiftyTwoWeekRange": "1.085 - 3.72", "fiftyTwoWeekHighChange": -1.82, "fiftyTwoWeekHighChangePercent": -0.48924732, "fiftyTwoWeekChangePercent": -41.666668, "earningsTimestamp": 1762435800, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.61, "epsForward": -1.28667, "epsCurrentYear": -1.52, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1601645400000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.9, "postMarketChange": 0.0, "regularMarketChange": -0.060000062, "regularMarketDayRange": "1.83 - 1.96", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1640470, "regularMarketChangePercent": -3.0612276, "regularMarketPrice": 1.9, "displayName": "C4 Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]